Mobile

Clinical study to evaluate the efficacy and safety of an antiallergic therapy, which will be administered against rhinitis and/or rhinoconjunctivitis with or without intermittent asthma as allergic re...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-004185-14

Clinical study to evaluate the efficacy and safety of an antiallergic therapy, which will be administered against rhinitis and/or rhinoconjunctivitis with or without intermittent asthma as allergic reaction to birch pollen. The study drug Depiquick® Birch used for this immunotherapy is a chemically modified extract of birch pollen

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate superiority of Depiquick® Birch (1,000 DPP/mL) over Depiquick®-matching placebo (0 DPP/mL) with regard to efficacy of intraseasonal SIT as assessed by the combined symptom and medication score (SMS) for rhinitis/rhinoconjunctivitis on the basis of the primary tree pollen exposition time.

Critère d'inclusion

  • Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma

Liens